日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma

idecabtagene vicleucel（ide-cel，bb2121）治疗日本复发难治性多发性骨髓瘤患者的II期临床试验结果

期刊:International Journal of Hematology
影响因子:1.8
doi:10.1007/s12185-023-03538-6
Minakata, Daisuke; Ishida, Tadao; Ando, Kiyoshi; Suzuki, Rikio; Tanaka, Junji; Hagiwara, Shotaro; Ananthakrishnan, Revathi; Kuwayama, Shigeki; Nishio, Mitsufumi; Kanda, Yoshinobu; Suzuki, Kenshi
多发性骨髓瘤
骨髓瘤
发表日期：2023
文献求助 收藏

An overview of the BOIN design and its current extensions for novel early-phase oncology trials

BOIN 设计概述及其目前在新型早期肿瘤试验中的扩展

期刊:Contemporary Clinical Trials Communications
影响因子:1.4
doi:10.1016/j.conctc.2022.100943
Ananthakrishnan, Revathi; Lin, Ruitao; He, Chunsheng; Chen, Yanping; Li, Daniel; LaValley, Michael
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacy

二维TEQR设计用于确定安全性和有效性的最佳剂量

期刊:Contemporary Clinical Trials Communications
影响因子:1.4
doi:10.1016/j.conctc.2019.100461
Ananthakrishnan, Revathi; Green, Stephanie; Li, Daniel; LaValley, Michael
发表日期：2019
文献求助 收藏

Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials

mTPI 和 TEQR 设计方案的扩展，除了毒性之外，还纳入了非单调疗效，以便为早期免疫治疗肿瘤试验确定最佳剂量。

期刊:Contemporary Clinical Trials Communications
影响因子:1.4
doi:10.1016/j.conctc.2018.01.006
Ananthakrishnan, Revathi; Green, Stephanie; Li, Daniel; LaValley, Michael
肿瘤
毒理研究
肿瘤免疫
免疫/内分泌
发表日期：2018
文献求助 收藏

Systematic comparison of the statistical operating characteristics of various Phase I oncology designs

对各种 I 期肿瘤学试验方案的统计操作特性进行系统比较

期刊:Contemporary Clinical Trials Communications
影响因子:1.4
doi:10.1016/j.conctc.2016.11.006
Ananthakrishnan, Revathi; Green, Stephanie; Chang, Mark; Doros, Gheorghe; Massaro, Joseph; LaValley, Michael
肿瘤
肿瘤免疫
发表日期：2017
文献求助 收藏

Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma

inotuzumab ozogamicin联合R-GDP治疗复发/难治性CD22+ B细胞非霍奇金淋巴瘤患者的I期研究

期刊:JOURNAL OF DRUG ASSESSMENT
影响因子:
doi:10.1080/21556660.2017.1315336
Sangha, Randeep; Davies, Andrew; Dang, Nam H; Ogura, Michinori; MacDonald, David A; Ananthakrishnan, Revathi; Paccagnella, M Luisa; Vandendries, Erik; Boni, Joseph; Goh, Yeow Tee
B细胞
淋巴瘤
CD22
细胞生物学
CD2
免疫/内分泌
发表日期：2017
文献求助 收藏

Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma

替西罗莫司治疗儿童高级别胶质瘤、神经母细胞瘤和横纹肌肉瘤的II期临床试验

期刊:European Journal of Cancer
影响因子:7.1
doi:10.1016/j.ejca.2011.09.021
Geoerger, Birgit; Kieran, Mark W; Grupp, Stephan; Perek, Danuta; Clancy, Jill; Krygowski, Mizue; Ananthakrishnan, Revathi; Boni, Joseph P; Berkenblit, Anna; Spunt, Sheri L
胶质瘤
横纹肌肉瘤
细胞生物学
发表日期：2012
文献求助 收藏

Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors

替西罗莫司治疗复发/难治性实体瘤患儿的I期研究

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.2010.33.4649
Spunt, Sheri L; Grupp, Stephan A; Vik, Terry A; Santana, Victor M; Greenblatt, David J; Clancy, Jill; Berkenblit, Anna; Krygowski, Mizue; Ananthakrishnan, Revathi; Boni, Joseph P; Gilbertson, Richard J
发表日期：2011
文献求助 收藏

A mitotic kinesin-6, Pav-KLP, mediates interdependent cortical reorganization and spindle dynamics in Drosophila embryos

有丝分裂驱动蛋白-6 Pav-KLP 介导果蝇胚胎中相互依赖的皮层重组和纺锤体动力学

期刊:Journal of Cell Science
影响因子:3.6
doi:10.1242/jcs.064048
Sommi, Patrizia; Ananthakrishnan, Revathi; Cheerambathur, Dhanya K; Kwon, Mijung; Morales-Mulia, Sandra; Brust-Mascher, Ingrid; Mogilner, Alex
Drosophila
发表日期：2010
文献求助 收藏

The forces behind cell movement

细胞运动背后的力量

期刊:International Journal of Biological Sciences
影响因子:10
doi:10.7150/ijbs.3.303
Ananthakrishnan, Revathi; Ehrlicher, Allen
细胞生物学
发表日期：2007
文献求助 收藏